ArticleHuman vaccines & immunotherapeutics2021

SARS‑CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice.

Jeroen Pollet et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.